Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Guibai Liang has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. ARCORIA, PAUL JOSEPH is the busiest examiner, managing 1 busiest examiner pending action. This 1 busiest examiner pending action represents the total 1 pending office action for this individual. The focus on 1 distinct art unit indicates a specific biological or pharmaceutical invention is currently under review.
Because there is only 1 pending office action, the immediate patent strategy is concentrated on a single point of contact within the USPTO. This lack of diversification in examiners or art units means that the current patent prospects are tied to the evaluation of ARCORIA, PAUL JOSEPH within that 1 distinct art unit. Practitioners should focus on the specific preferences and history of this 1 distinct examiner. The alignment of 1 distinct examiner and 1 distinct art unit suggests a narrow and specific focus in the current biotech filings. This 1 pending office action is the only one currently being evaluated for Guibai Liang.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARCORIA, PAUL JOSEPH | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18598315 | SUBSTITUTED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | ARCORIA, PAUL JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18598315 | SUBSTITUTED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | ARCORIA, PAUL JOSEPH | 1621 | §102§103§112 | Non-Final OA | — | Pending | Mar 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGuibai Liang has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Paul Joseph Arcoria has the most, with 1 of Guibai Liang's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
